The Novacyt Group is a leader in the field of cellular diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform NOVAPREP® and a strong international network Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

Latest Share Price

EPA:ALNOV - 07 Dec 05:53 GMT+1

1.12+0.00 (+0.00%)

Latest News

08 November 2016

NOVACYT WINS TECHNOLOGY FAST 50 AWARD

LEARN MORE

“We value your interest in Novacyt and taking the time to look at our web site. I am proud to be part of a dynamic, international business with an exciting portfolio of diagnostic platform products. At the heart of our business is the team of people with the skills and experience to execute our vision and objectives. I hope you will find our energetic, “can-do” culture rewarding irrespective of whether you are a customer, supplier, investor, employee or stake-holder of the business.”
Graham Mullis – CEO